James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).

Click here to read the full article: thelancet.com/journals/lanonc/article/PIIS1470…)00762-4/fulltext?dgcid=podcast_acq-april26_lanonc

Tell us what you thought about this episode (buzzsprout.com/1391338/fan_mail/new)

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.

You can visit thelancet.com/medical-imaging-theranostics?dgc… to learn more.

Continue this conversation on social!

Follow us today at...

thelancet.bsky.social

instagram.com/thelancetgroup

facebook.com/thelancetmedicaljournal

linkedIn.com/company/the-lancet (linkedin.com/company/the-lancet)

youtube.com/thelancettv